Reading COCH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COCH free→Reading COCH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COCH free→QuarterlyIQ Insights · COCH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on November 19, 2025, Envoy Medical, Inc. (the “Company”), received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the “Common Stock”), had failed to comply with the $1.00 minimum bid price required for con…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 12, 2026, Envoy Medical, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”). At the Annual Meeting, the Company’s stockholders (the “ Stockholders ”) approved (the “ Stockholder Approval ”): (i) an amendment to the Company’s 2023 Equity Incentive Plan (the “ Equity Incentive Plan ”) to authorize an a…
Results of Operations and Financial Condition. On May 11, 2026, Envoy Medical, Inc. (the “Company”), issued a press release regarding the Company’s financial results for its fiscal quarter ended March 31, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “ Board ”) of Envoy Medical, Inc. (the “ Company ”), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders. In connection with and effective as of his appointment to t…
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm The Audit Committee (the “ Committee ”) of the Board of Directors of Envoy Medical, Inc. (the “ Company ”) conducted a competitive process to select the audit firm to serve as the Company’s independent registered public accounting firm beginning with the fiscal year ending December 31, 2026. At the conclusion of that process, EisnerAmper LLP (“ EisnerAmper ”) was appointed to serve as…
Results of Operations and Financial Condition. On March 23, 2026, Envoy Medical, Inc. (the “Company”), issued a press release regarding the Company’s financial results for its fourth fiscal quarter and fiscal year ended December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 23, 2026, Envoy Medical, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a discre…
Entry into a Material Definitive Agreement On February 11, 2026, Envoy Medical, Inc., a Delaware corporation (the “ Company ”), commenced a best efforts public offering (the “ Offering ”) of an aggregate of (i) 47,946,150 shares (the “ Shares ”) of the Company’s Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), (ii) 27,053,850 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 27,053,850 shares of Common Stock, (iii) 45,000,000 Series A-1 Warrants to purchase 45…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 5, 2026 (the “ Award Date ”), the Compensation Committee of the Board of Directors of Envoy Medical, Inc. (the “ Company ”) approved the issuance of stock options to the Company’s Chief Executive Officer, Brent Lucas, and its Interim Chief Financial Officer, Robert Potashnick under the Company’s 2023 Equity Incentive Plan, as amended (th…
Entry into a Material Definitive Agreement. Envoy Medical, Inc. (the “ Company ”) has previously issued Stock Purchase Warrants (as amended to date, the “ Shortfall Warrants ”) to Meteora Special Opportunity Fund I, LP (“ MSOF ”), Meteora Capital Partners, LP (“ MCP ”), Meteora Select Trading Opportunities Master, LP (“ MSTO ”) and Meteora Strategic Capital, LLC (“ MSC ” and, collectively with MSOF, MCP and MSTO, the “ Meteora Parties ”) pursuant to the terms of the Equity Prepaid Forward Tra…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 19, 2025, Envoy Medical, Inc. (the “Company”) received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the "Common Stock"), has failed to comply with the $1.00 minimum bid price required for continued listing on The Nasd…
Results of Operations and Financial Condition. On November 10, 2025, Envoy Medical, Inc. (the “Company”), issued a press release regarding the Company’s financial results for its third fiscal quarter ended September 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 23, 2025, the Nasdaq Hearings Panel (the “Panel”) notified Envoy Medical, Inc. (the “Company) that it has granted the Company’s request for an exception to demonstrate compliance with the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) for continued listing through February 23, 2026 (the “Exception”). Pur…
Other Events. On October 8, 2025, the Company issued a press release announcing the pricing of the Offering described above, a copy of which is attached as Exhibit 99.1 hereto. 2 Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K other than statements of historical facts, including statemen…
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement On October 7, 2025, Envoy Medical, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited and institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Purchasers (the “Registered Offering”) 3,007,524 shares (the “Shares”) of Class A common stock,…
Entry into a Material Definitive Agreement On September 22, 2025, Envoy Medical, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited and institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Purchasers (the “Registered Offering”) 1,908,402 shares (the “Shares”) of Class A common stoc…
Other Events. On September 22, 2025, the Company issued a press release announcing the pricing of the Offering described above, a copy of which is attached as Exhibit 99.1 hereto. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K other than statements of historical facts, including stateme…
Unregistered Sales of Equity Securities. The information set forth in
Entry into Material Definitive Agreement On September 4, 2025, Envoy Medical, Inc. (the “ Company ”) entered into a Voting and Warrant Extension Agreement (the “ Voting and Extension Agreement ”) with Glen A. Taylor (“ Taylor ”), GAT Funding, LLC (“ GAT ”), and Taylor Sports Group, Inc. (“ Taylor Sports ” and, together with GAT and Taylor, the “ Taylor Parties ”). GAT and Taylor Sports are controlled by Mr. Taylor who owns, directly or indirectly, approximately 47.8% of the Company’s outstand…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on February 25, 2025, Envoy Medical, Inc. (the “Company”) received a deficiency notification letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the market value of the Company’s listed securities did not meet the minimum of $35,000,000 (the “MVLS Requireme…
Termination of a Material Definitive Agreement On August 25, 2025, Envoy Medical, Inc. (the “Company”) entered into a Satisfaction of Promissory Notes (the “Satisfaction Agreement”) with GAT Funding, LLC (“GAT Funding”), an entity controlled by the Company’s largest stockholder, Glen Taylor. Pursuant to the terms of the Satisfaction Agreement, all of the Company’s obligations under promissory notes issued to GAT Funding on February 27, 2024, August 27, 2024, and March 6, 2025, respectively, e…
below is attached hereto as Exhibit 99.1. The information set forth Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Exhibit 99.1 shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by speci…
Results of Operations and Financial Condition. On July 31, 2025, Envoy Medical, Inc. (the “Company”), issued a press release regarding the Company’s financial results for its second fiscal quarter ended June 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
Entry into a Material Definitive Agreement. Envoy Medical, Inc. (the “ Company ”) has previously issued Stock Purchase Warrants (the “ Shortfall Warrants ”) to Meteora Special Opportunity Fund I, LP (“ MSOF ”), Meteora Capital Partners, LP (“ MCP ”), Meteora Select Trading Opportunities Master, LP (“ MSTO ”) and Meteora Strategic Capital, LLC (“ MSC ” and, collectively with MSOF, MCP and MSTO, the “ Meteora Parties ”) pursuant to the terms of the Equity Prepaid Forward Transaction, dated as o…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.